TY - JOUR T1 - Could severe COVID-19 be considered a complementopathy? JF - Lupus Science & Medicine JO - Lupus Sci Med DO - 10.1136/lupus-2020-000415 VL - 7 IS - 1 SP - e000415 AU - Katerina Chatzidionysiou AU - Elisabet Svenungsson AU - Francesca Faustini Y1 - 2020/05/01 UR - http://lupus.bmj.com/content/7/1/e000415.abstract N2 - COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS), observed in most critically ill cases with SARS-CoV-2, is a life-threatening inflammatory lung injury.1 It necessitates hospitalisation, oxygen supplementation and in some cases mechanical ventilation, and is associated with high mortality rates, reaching around 40%.2 It is the effects of an over-reacting immune system, rather than the viral load, which are believed to cause ARDS. A cytokine storm characterised by proinflammatory cytokines, such as interleukin (IL)-1 and IL-6, together with hypercoagulability is seen in a majority of hospitalised patients. Elevated D-dimer, lactate dehydrogenase and fibrinogen and clinical thromboembolic manifestations, such as pulmonary emboli, are common features of severe COVID-19. Zhang et al 3 recently reported significant coagulopathy with multiple infarctions accompanied by prothrombotic antiphospholipid antibodies in three cases of COVID-19. Endothelial damage, … ER -